NCT06388148 Endovascular Treatment for eXtra-Large Ischemic Stroke
| NCT ID | NCT06388148 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongming Qiu |
| Condition | Stroke, Acute Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 286 participants |
| Start Date | 2024-06-16 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 286 participants in total. It began in 2024-06-16 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older; 2. Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if \> 6 hours or unknown last known well time; 3. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA/MRA/DSA; 4. Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml; 5. The patient or patient's representative signs a written informed consent form. Exclusion Criteria: 1. CT or MR evidence of hemorrhage; 2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging; 3. Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access; 4. History of bleeding disorders, severe heart, liver or kidney disease, or sepsis; 5. Currently participating in another investigational drug study; 6. Any terminal illness with life expectancy less than 6 months.
Contact & Investigator
Guangxiong Yuan
PRINCIPAL INVESTIGATOR
Xiangtan Central Hospital
Frequently Asked Questions
Who can join the NCT06388148 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Acute Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06388148 currently recruiting?
Yes, NCT06388148 is actively recruiting participants. Contact the research team at ruanzhongfan@sina.com for enrollment information.
Where is the NCT06388148 trial being conducted?
This trial is being conducted at Hengyang, China, Xiangtan, China.
Who is sponsoring the NCT06388148 clinical trial?
NCT06388148 is sponsored by Zhongming Qiu. The principal investigator is Guangxiong Yuan at Xiangtan Central Hospital. The trial plans to enroll 286 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.